Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

The Impact of Symptom Severity on Multidisciplinary Tumor Board Treatment Decisions

2021 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

At the Institute for Oncology and Radiology of Serbia (IORS), the partnership between the supportive care team (SCT) and the multidisciplinary tumor board (MTB) for patients with advanced cancer has progressed. A study was performed to assess symptom load in referred patients and investigate how it relates to MTB treatment decisions.1

Patients with advanced cancer were referred to the MTB with the option of receiving either anticancer treatment or active symptom control. The SCT used the Edmonton Symptom Assessment System - Revised (ESAS-r) to assess 6 physical symptoms, depression, anxiety, and overall well-being reported by patients upon admission. The link between MTB treatment decision and the individual symptom/overall well-being score (0-10; higher = worse) as well as the composite ESAS-physical and ESAS-total score was investigated.1

Since November 2018, a total of 136 patients have been referred (median age, 63 years; range, 19-86 years). Gastrointestinal cancer was the most prevalent, followed by genitourinary cancer and lung cancer. The most common reasons for MTB referral were pain (94.1%), reduced well-being (89.7%), and fatigue (77.94%). There was no link between the severity of patients’ symptoms (ESAS-total and physical) and their MTB treatment decision. Although pain, fatigue, and reduced well-being were all reported to be considerable, they were not linked to the MTB treatment decision within the IORS study. Within this study, patients were referred directly by the MTB, which allowed the SCT to get involved early and for patients to disclose their symptom burden. Feedback on patients’ symptom burden from the SCT to the MTB could be utilized to aid therapeutic decision-making and help prioritize treatments for patients with advanced cancer to receive anticancer treatment or active symptom control.1

Within the IORS study, symptom severity was not linked to MTB treatment decisions. MTBs collaborate closely to make clinical choices in cancer therapy and are expected to improve patient and organizational outcomes. A multidisciplinary approach is the most effective way to provide the complex care that patients with cancer require; however, it is a challenge that requires organizational interventions, as well as the leadership of competent health executives who can improve teamwork within their organizations.2 The cornerstone to cancer treatment is multidisciplinary care and data suggest that multidisciplinary care facilitates high-quality cancer treatment, which may lead to increased survival in patients with cancer, their treatment adherence, and improved quality of life.3

References

  1. Djordjevic FR, Calamac M, Bosnjak SM, et al. Patients with advanced cancer referred to a supportive care team (SCT) from a multidisciplinary tumor board (MTB): symptom burden and its relationship with MTB treatment decision. Ann Oncol. 2021;32(suppl 5):S1194.
  2. Specchia ML, Frisicale EM, Carini E, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res. 2020;20:73.
  3. Hardavella G, Frille A, Theochari C, et al. Multidisciplinary care models for patients with lung cancer. Breathe (Sheff). 2020;16:200076.
Related Items
NSCLC Year in Review Introduction
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Targeted Therapy and Immunotherapy May Improve NSCLC Survival Rates
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
CodeBreaK 100 Phase 2 Study Results Demonstrate Sotorasib Efficacy
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
FDA Grants Accelerated Approval of Sotorasib for Patients with NSCLC Harboring KRAS Mutations
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Role of Exercise and Energy Conservation in the Management of Fatigue in Patients with NSCLC Receiving Immune-Oncology Therapy
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Impact of Hyperglycemia in Patients with Advanced NSCLC with PD-L1 ≥50% Treated with Frontline Pembrolizumab
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
A Retrospective Study Shows Different Lung Imaging Patterns Among Different Cancer Types
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Sotorasib Demonstrates Clinical Benefit in Patients with NSCLC and KRASᴳ¹²ᶜ
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Anxiety and Depression Among Oncology-Treated Patients with Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Breaking the Barriers to NGS Testing in Oncology Care: Physician-Reported Strategies
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.